"Men"

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

Approval for new FIC depression drug on the horizon!

Osteoporosis is the cause of menopausal fractures! Do these 5 things to avoid osteoporosis

Every September is the "World Alzheimer's Disease Month". In 2022, the theme of "World Alzheimer's Disease Month" is "Know Dementia, Know Alzheimer's - Another, we can do so much". It aims to continue to focus on early screening and early diagnosis, and focus on publicizing the 10 early symptoms, 12 risk factors that can be intervened and medical and social support after diagnosis of Alzheimer's disease, so as to achieve the goal of overall management of Alzheimer's disease

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

An obvious feature of autumn that is different from summer is that the temperature drops, the weather is unpredictable, and the temperature difference between morning and night is large, which has become one of the main causes of female biological clock disorder, endocrine disorder and bacterial infection in autumn. In addition, the resistance of the human body decreases relatively in autumn, which is also a time of high recurrence for patients with gynecological diseases.

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!